Detection of Cytokeratin-Positive Cells in Bone Marrow in Breast Cancer and Colorectal Carcinoma in Comparison with Other Factors of Prognosis
- 1 December 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy & Stem Cell Research
- Vol. 9 (6) , 905-911
- https://doi.org/10.1089/152581600750062354
Abstract
A prospective study is presented in which 293 patients suffering from breast cancer and colorectal carcinoma were analyzed for prognostic relevance of detected isolated disseminated tumor cells in bone marrow (IDTBM). The patients underwent surgery in the period from 1995 to 1997 and remained under observation until 1999. The monoclonal antibody A 45-B/B3 was used in the standard immuno-cytochemical method for detecting IDTBM, which represented an independent prognostic factor for survival time in patients with breast cancer or colorectal cancer. In breast cancer, when IDTBM were detected, the survival period was reduced by at least half. When disseminated tumor cells containing the A45-B/B3 antibody were detected in bone marrow, the risk of an earlier relapse of the tumor increased at least fourfold. In colorectal cancer, detection of IDTBM reduced survival time by a factor of 1.2–4.3. The risk of earlier relapse increased when disseminated tumor cells containing the A45-B/B3 antibody were detected in bone marrow by 2.8–8.1. Therefore, the use of IDTBM as an independent prognostic factor would provide an important method for determining the pathological stage of various cancers. Standardization of this technique into a generally accepted method would be especially desirable in treatment of patients with breast or colorectal cancer.Keywords
This publication has 14 references indexed in Scilit:
- Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.Journal of Clinical Oncology, 1998
- Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.Journal of Clinical Oncology, 1998
- Disseminierte Tumorzellen: Diagnostik, prognostische Relevanz, Phänotypisierung und therapeutische StrategienDer Chirurg, 1997
- Prognostic relevance of occult tumor cells in lymph nodes of colorectal carcinomasDiseases of the Colon & Rectum, 1997
- "Knochenmarksmikrometastasen" epithelialer TumorenDer Onkologe, 1997
- Tumorzelldissemination in das Knochenmark und in die Peritonealhohle eine immunzytochemische Untersuchung an Patienten mit einem Magen- oder kolorektalen KarzinomLangenbecks Archives Of Surgery, 1996
- Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinomaThe Lancet, 1994
- Immunocytological detection of micrometastatic cells: Comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patientsInternational Journal of Cancer, 1994
- Methodological Analysis of Immunocytochemical Screening for Disseminated Epithelial Tumor Cells in Bone MarrowJournal of Hematotherapy, 1994
- Monoclonal Antibodies Detect Occult Breast Carcinoma Metastases in the Bone Marrow of Patients with Early Stage DiseaseThe American Journal of Surgical Pathology, 1988